ExodusPoint Capital Management’s Riskified RSKD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$127K Sell
32,399
-25,324
-44% -$112K ﹤0.01% 1423
2025
Q4
$287K Sell
57,723
-6,639
-10% -$32K ﹤0.01% 1321
2025
Q3
$301K Buy
+64,362
New +$317K ﹤0.01% 1307
2025
Q1
Sell
-200,991
Closed -$951K 1929
2024
Q4
$951K Buy
200,991
+157,657
+364% +$731K 0.01% 962
2024
Q3
$205K Buy
+43,334
New +$237K ﹤0.01% 1451
2024
Q2
Sell
-93,331
Closed -$505K 1920
2024
Q1
$505K Buy
93,331
+37,199
+66% +$177K ﹤0.01% 1139
2023
Q4
$263K Buy
56,132
+10,484
+23% +$42.9K ﹤0.01% 1215
2023
Q3
$205K Sell
45,648
-35,698
-44% -$164K ﹤0.01% 1518
2023
Q2
$395K Buy
+81,346
New +$408K ﹤0.01% 1441
2022
Q2
Sell
-45,189
Closed -$273K 2375
2022
Q1
$273K Sell
45,189
-23,920
-35% -$160K ﹤0.01% 1797
2021
Q4
$543K Buy
+69,109
New +$988K 0.01% 1355

Other funds holding RSKD

ExodusPoint Capital Management's RSKD Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Riskified (RSKD) stake by 44% in Q1 2026, selling an estimated $112K and leaving 32,399 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1423.

ExodusPoint Capital Management first reported a position in RSKD in Q4 2021 and has held it in 11 quarters since. The position peaked at $951K in Q4 2024. 105 funds tracked by Wall St. Rank hold RSKD as of Q1 2026.

  • ExodusPoint Capital Management held 32,399 shares of Riskified worth $127K as of Q1 2026.
  • ExodusPoint Capital Management sold 25,324 Riskified shares in Q1 2026, an estimated $112K.
  • Riskified made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1423 holding.
  • ExodusPoint Capital Management first reported a position in Riskified in Q4 2021 and has held it in 11 quarters since.
  • ExodusPoint Capital Management's Riskified position peaked at $951K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Riskified as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.